arrow
R

Raja Atreya

deutsches zentrum immuntherapie
H指数:67
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Feasibility and expert evaluation of a medical large language model in an interdisciplinary clinical board

一种医学大型语言模型在跨学科临床委员会中的可行性与专家评估

2026-10-020
OAAI
Persistence of mucosal CAR-T cells and inflammatory remodeling in enterocolitis associated with BCMA CAR-T cell therapy

与BCMA car-t细胞治疗相关的小肠结肠炎中粘膜car-t细胞的持久性和炎症重塑

2026-09-230
PRE
Effect of Mirikizumab on Clinical and Endoscopic Outcomes Based on Prior Advanced Therapy Failure in Patients With Moderately to Severely Active Ulcerative Colitis

基于先前高级别治疗失败的活动中度至重度溃疡性结肠炎患者中米里克珠单抗对临床和内镜结局的影响

2026-05-010
OAAI
Targeting the transcription factor GATA3 by the DNAzyme formulation SB012 in patients with moderately-to-severely active ulcerative colitis: a multicenter, randomized, placebo-controlled, phase 2a induction trial

靶向转录因子GATA3的DNAzyme制剂SB012在中等至重度活动性溃疡性结肠炎患者中的治疗:一项多中心、随机、安慰剂对照的2a期诱导试验

2026-05-010
PRE
Efficacy and health-related quality of life associated with second-line vedolizumab after first-line treatment with one anti-TNF in patients with ulcerative colitis: a meta-analysis of the GEMINI-1 and VISIBLE-1 trials

溃疡性结肠炎患者经一种抗-TNF作为一线治疗后,接受二线 vedolizumab 治疗的疗效与健康相关生活质量:GEMINI-1 和 VISIBLE-1 试验的荟萃分析

2026-03-230
OA
Successful treatment of severe retroauricular pyoderma gangrenosum with upadacitinib in a patient with Crohn’s disease and a history of cerebral venous sinus thrombosis

一名患有克罗恩病且有过脑静脉窦血栓病史的患者,采用乌帕替尼成功治疗严重耳后坏疽性脓皮病。

2026-02-220
OA
Definitions, diagnosis, management, and outcomes of upper gastrointestinal Crohn's disease: an international, expert RAND/UCLA appropriateness study

定义、诊断、管理及上消化道克罗恩病的结局:一项国际专家RAND/UCLA适宜性研究

2026-01-080
PRE
Pooled analysis of efficacy and safety of once-daily oral obefazimod in European patients from the ABTECT Phase 3, double-blind, placebo-controlled induction trials

欧洲患者中每日一次口服奥贝非米德在ABTECT III期、双盲、安慰剂对照诱导试验中的疗效和安全性的合并分析

2026-01-010
PRE
Obefazimod enhances miR-124 expression in blood and colon tissue and reduces the key inflammatory cytokines IL-17A and IL-6 in serum of patients with moderate-to-severely active ulcerative colitis: results from the Phase 3 ABTECT induction trials

奥贝法西莫德增强溃疡性结肠炎患者血液和结肠组织中miR-124的表达,并降低血清中的关键炎症细胞因子IL-17A和IL-6:来自第3期ABTECT诱导试验的结果

2026-01-010
PRE
Early symptomatic improvement with obefazimod in patients with moderately to severely active ulcerative colitis: pooled results from the ABTECT-1 and ABTECT-2 Phase 3, double-blind, placebo-controlled induction trials

奥贝非齐模德治疗中重度活动性溃疡性结肠炎患者的早期症状改善:ABTECT-1和ABTECT-2两项III期、双盲、安慰剂对照诱导试验的合并结果

2026-01-010
PRE
Impact of baseline body mass index (BMI) on efficacy of obefazimod in patients with moderately to severely active ulcerative colitis: results from the Phase 3 ABTECT induction trials

基线体重指数(BMI)对中重度活动性溃疡性结肠炎患者奥贝芬米德疗效的影响:来自第3期ABTECT诱导试验的结果

2026-01-010
PRE